Literature DB >> 14674677

Characterization of the inhibitory effects of erythromycin and clarithromycin on the HERG potassium channel.

Scott J C Stanat1, Carol G Carlton, William J Crumb, Krishna C Agrawal, Craig W Clarkson.   

Abstract

Both erythromycin and clarithromycin have been reported to cause QT prolongation and the cardiac arrhythmia torsade de pointes in humans, however direct evidence documenting that these drugs produce this effect by blocking human cardiac ion channels is lacking. The goal of this study was to test the hypothesis that these macrolide antibiotics significantly block the delayed rectifier current (IKr) encoded by HERG (the human ether-a-go-go-related gene) at drug concentrations, temperature and ionic conditions mimicking those occurring in human subjects. Potassium currents in HEK 293 cells stably transfected with HERG were recorded using a whole cell voltage clamp method. Exposure of cells to erythromycin reduced the HERG encoded potassium current in a concentration dependent manner with an IC50 of 38.9 +/- 1.2 microM and Hill Slope factor of 0.4 +/- 0.1. Clarithromycin produced a similar concentration-dependent block with an IC50 of 45.7 +/- 1.1 microM and Hill Slope factor of 1.0 +/- 0.1. Erythromycin (25-250 microM) and clarithromycin (5 or 25 microM) also produced a significant decrease in the integral of the current evoked by an action potential shaped voltage clamp protocol. The results of this study document that both erythromycin and clarithromycin significantly inhibit the HERG potassium current at clinically relevant concentrations.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14674677     DOI: 10.1023/a:1027309703313

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  24 in total

1.  A review of erythromycin-induced malignant tachyarrhythmia--torsade de pointes. A case report.

Authors:  K Katapadi; G Kostandy; M Katapadi; K M Hussain; D Schifter
Journal:  Angiology       Date:  1997-09       Impact factor: 3.619

2.  Erythromycin-induced long QT syndrome: concordance with quinidine and underlying cellular electrophysiologic mechanism.

Authors:  S Nattel; S Ranger; M Talajic; R Lemery; D Roy
Journal:  Am J Med       Date:  1990-08       Impact factor: 4.965

3.  Association of intravenous erythromycin and potentially fatal ventricular tachycardia with Q-T prolongation (torsades de pointes).

Authors:  R A Schoenenberger; W E Haefeli; P Weiss; R F Ritz
Journal:  BMJ       Date:  1990-05-26

4.  Properties of HERG channels stably expressed in HEK 293 cells studied at physiological temperature.

Authors:  Z Zhou; Q Gong; B Ye; Z Fan; J C Makielski; G A Robertson; C T January
Journal:  Biophys J       Date:  1998-01       Impact factor: 4.033

5.  Cellular and ionic mechanisms underlying erythromycin-induced long QT intervals and torsade de pointes.

Authors:  C Antzelevitch; Z Q Sun; Z Q Zhang; G X Yan
Journal:  J Am Coll Cardiol       Date:  1996-12       Impact factor: 24.094

6.  Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches.

Authors:  O P Hamill; A Marty; E Neher; B Sakmann; F J Sigworth
Journal:  Pflugers Arch       Date:  1981-08       Impact factor: 3.657

Review 7.  Erythromycin-induced QT prolongation and polymorphic ventricular tachycardia (torsades de pointes): case report and review.

Authors:  M W Brandriss; W S Richardson; S S Barold
Journal:  Clin Infect Dis       Date:  1994-06       Impact factor: 9.079

8.  Erythromycin binding to human serum.

Authors:  G A Dette; H Knothe; G Herrmann
Journal:  Biochem Pharmacol       Date:  1982-03-15       Impact factor: 5.858

9.  QT interval prolongation and torsades de pointes due to erythromycin lactobionate.

Authors:  K C Oberg; J L Bauman
Journal:  Pharmacotherapy       Date:  1995 Nov-Dec       Impact factor: 4.705

10.  Erythromycin blocks the rapid component of the delayed rectifier potassium current and lengthens repolarization of guinea pig ventricular myocytes.

Authors:  P Daleau; E Lessard; M F Groleau; J Turgeon
Journal:  Circulation       Date:  1995-06-15       Impact factor: 29.690

View more
  22 in total

1.  Blinded validation of the isolated arterially perfused rabbit ventricular wedge in preclinical assessment of drug-induced proarrhythmias.

Authors:  Tengxian Liu; Barry S Brown; Ying Wu; Charles Antzelevitch; Peter R Kowey; Gan-Xin Yan
Journal:  Heart Rhythm       Date:  2006-04-22       Impact factor: 6.343

2.  Giant inverted T waves and substantial QT interval prolongation induced by azithromycin in an elderly woman with renal insufficiency.

Authors:  Tongtong Yu; Tiesheng Niu
Journal:  Can Fam Physician       Date:  2014-11       Impact factor: 3.275

3.  Allosteric effects of erythromycin pretreatment on thioridazine block of hERG potassium channels.

Authors:  W J Crumb
Journal:  Br J Pharmacol       Date:  2014-04       Impact factor: 8.739

Review 4.  Cardiovascular safety of prokinetic agents: A focus on drug-induced arrhythmias.

Authors:  J R Giudicessi; M J Ackerman; M Camilleri
Journal:  Neurogastroenterol Motil       Date:  2018-02-14       Impact factor: 3.598

5.  Pregnancy outcome after gestational exposure to erythromycin - a population-based register study from Norway.

Authors:  Maria Romøren; Morten Lindbæk; Hedvig Nordeng
Journal:  Br J Clin Pharmacol       Date:  2012-12       Impact factor: 4.335

Review 6.  Exposure to antibacterial agents with QT liability in 14 European countries: trends over an 8-year period.

Authors:  Emanuel Raschi; Elisabetta Poluzzi; Chiara Zuliani; Arno Muller; Herman Goossens; Fabrizio De Ponti
Journal:  Br J Clin Pharmacol       Date:  2008-11-17       Impact factor: 4.335

7.  Clarithromycin, QTc interval prolongation and torsades de pointes: the need to study case reports.

Authors:  W Victor R Vieweg; Jules C Hancox; Mehrul Hasnain; Jayanthi N Koneru; Michael Gysel; Adrian Baranchuk
Journal:  Ther Adv Infect Dis       Date:  2013-08

8.  Azithromycin, cardiovascular risks, QTc interval prolongation, torsade de pointes, and regulatory issues: A narrative review based on the study of case reports.

Authors:  Jules C Hancox; Mehrul Hasnain; W Victor R Vieweg; Ericka L Breden Crouse; Adrian Baranchuk
Journal:  Ther Adv Infect Dis       Date:  2013-10

9.  The cardiovascular and pharmacokinetic profile of dofetilide in conscious telemetered beagle dogs and cynomolgus monkeys.

Authors:  T M Haushalter; G S Friedrichs; D L Reynolds; M Barecki-Roach; G Pastino; R Hayes; A S Bass
Journal:  Br J Pharmacol       Date:  2008-07-07       Impact factor: 8.739

10.  Targeting potassium channels and autophagy to defeat chemoresistance.

Authors:  Giulia Petroni
Journal:  Mol Cell Oncol       Date:  2020-03-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.